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A B S T R A C T
A standardized in vitro simulation of the human gastrointestinal tract (M-SHIME®) was used to assess the effect of
repeated daily administration of a synbiotic formulation, containing five spore-forming Bacillus strains and a
prebiotic fiber blend, on the microbial activity and composition of three simulated human subjects. Firstly, while
confirming recent findings, deeper phylogenetic insight was obtained in the resident M-SHIME® microbiota,
demonstrating that the model maintains a diverse and representative, colon region-specific luminal and mucosal
microbial community. Supplementation of the synbiotic concept increased microbial diversity in the distal colon
areas, whereas specific enhancement of Bacillaceae levels was observed in the ascending colon suggesting a
successful engraftment of the Bacillus spores, which probably resulted in a stimulatory effect on, among others,
Bifidobacteriaceae, Lactobacillaceae, Prevotellaceae, Tannerellaceae and Faecalibacterium prausnitzii contributing
directly or indirectly to stimulation of acetate, propionate and butyrate production. When compared with a
previous study investigating the Bacillus strains, the generated data suggest a synergistic effect on the intestinal
microbiota for the synbiotic formulation. Given the fact that the probiotic strains have been shown to impact
post-prandial metabolic endotoxemia in human individuals, it might be interesting to further investigate the
efficacy of the synbiotic concept in protecting against obesity-related disorders.
1. Introduction
A strategy to improve intestinal health is the use of prebiotics,
probiotics and synbiotics. While prebiotics have been defined as ‘non-
digestible substrates that are selectively used by the gut microbial
community, thereby conferring a health benefit for the host’ (Gibson
et al., 2017), probiotics consider the administration of live micro-
organisms that ‘when administered in adequate amounts, confer a
health benefit on the host’ (Hill et al., 2014). A synbiotic formulation
combines both concepts often aiming to provide synergistic effects in
the gastrointestinal tract as compared to the activity of the single
substrates and strains (Schrezenmeir and de Vrese, 2001). The most
commonly used prebiotics in synbiotic formulations comprise fibers
such as inulin, fructooligosaccharides (FOS), galactooligosaccharides
(GOS) and xylooligosaccharides (XOS), while the mostly used probiotic
strains include Lactobacillus spp., Bifidobacterium spp., Saccharomyces
boulardii and Bacillus coagulans (Pandey et al., 2015). Synbiotic sup-
plementation has been linked with several human health benefits, such
as improvement of atopic dermatitis (Farid et al., 2011), reduction of
serum lipid profile in patients with type-2 diabetes (Shakeri et al.,
2014), alleviation of digestive complaints in patients with gastro-
intestinal disorders (Fujimori et al., 2009; Šmid et al., 2016) and
changes in anthropometric measurements in obese individuals (Ipar
et al., 2015; Safavi et al., 2013).
Bacillus spp. have been widely used as probiotic ingredient in both
animals and humans as many of these species are adapted to survive in
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the host gastrointestinal tract (Hong et al., 2005). Indeed, Bacillus
species are able to form endospores, which protect the bacterial cell to
gastric acidity, followed by germination and further proliferation of the
micro-organism in the small intestine (Cartman et al., 2008; Casula and
Cutting, 2002; Tam et al., 2006). Such germination is a prerequisite for
certain health benefits as shown by Rhee et al. which reported stimu-
lation of gut-associated lymphoid tissue (GALT) development in infant
rabbits upon germination of orally administered Bacillus subtilis spores
(Rhee et al., 2004). Next to immunomodulation, germinating spores of
Bacillus subtilis var. Natto have been shown to secrete nattokinase, a
peptidase involved in fibrinolysis (Sumi et al., 1995). Recently, it was
reported that supplementation of a blend of five spore-forming Bacillus
strains reduced post-prandial metabolic endotoxemia in human in-
dividuals, likely by modulation of the gut microbial community
(McFarlin et al., 2017).
Recently, our research group evaluated the gut-modulatory effect of
the same probiotic formulation as used by McFarlin et al. in a validated
in vitro simulation of the human gastrointestinal tract for three different
adult donors (Duysburgh et al., 2019; McFarlin et al., 2017). Bifido-
bacterium levels increased for all three donors tested, while a donor-
dependent modulation of metabolic activity was revealed. Indeed, sig-
nificant stimulation of health-related metabolites acetate, propionate
and butyrate production was observed upon probiotic supplementation.
Further, donor-dependent effects were observed at microbial commu-
nity level, with two of the three donors stimulating Faecalibacterium
prausnitzii, whereas the final donor enriched Akkermansia muciniphila
upon probiotic administration. Interestingly, this related to observed in
vivo findings by Everard et al. who showed that stimulation of Akker-
mansia muciniphila reduced high-fat diet induced metabolic en-
dotoxemia (Everard et al., 2013), while González-Sarrías et al. showed a
significant association between decreased endotoxemia and increased
abundance of Faecalibacterium and Odoribacter in obese individuals
(Gonzalez-Sarrias et al., 2018).
In the present study, we aimed at evaluating the synbiotic effect of
the aforementioned probiotic mix of five strains in combination with a
functional fiber blend, in order to elucidate potential synergistic effects
on microbial metabolic activity and community composition of the
same three human individuals that were tested in the preceding in vitro
study (Duysburgh et al., 2019). For this purpose, the validated Mucosal
Simulator of the Human Intestinal Microbial Ecosystem (M-SHIME®)
was used, which allowed to evaluate the synbiotic effect of the test
product in three consecutive colon regions, both consisting of a luminal
and mucosal environment (Possemiers et al., 2004; Van den Abbeele
et al., 2012).
2. Materials and methods
2.1. Chemicals and test product
Unless otherwise stated, all chemicals were obtained from Sigma-
Aldrich (Overijse, Belgium). Microbiome Labs (Glenview, USA) pro-
vided the synbiotic formulation, consisting of MegaSporebiotic, a pro-
prietary probiotic mixture of Bacillus indicus (HU36), Bacillus subtilis
(HU58), Bacillus coagulans SC-208, Bacillus licheniformis and Bacillus
clausii SC-109 spores, and MegaPrebiotic, a proprietary prebiotic blend
of fructooligosaccharides from green and gold kiwifruit (Livaux™ and
ACTAZIN™), xylooligosaccharides from corn cob (PreticX™) and ga-
lactooligosaccharides from cow milk (Bimuno®). The daily synbiotic
dose contained 8 * 109 Bacillus spores, which corresponds to two cap-
sules of MegaSporeBiotic, and 3775mg of prebiotic blend.
2.2. Simulator of the human intestinal microbial ecosystem (SHIME®)
The reactor setup represented the different regions of the human
gastrointestinal tract and was adapted from the SHIME® (ProDigest and
Ghent University, Belgium) as previously described by Molly et al.
(1993). The SHIME® setup consists of a series of five reactors simulating
the stomach, small intestine and finally three colon compartments that
upon inoculation with the fecal microbiota from a healthy human in-
dividual represent the ascending (AC), transverse (TC) and descending
(DC) colon. During the current study, three SHIME® experiments were
conducted in parallel, differing in fecal microbiota used. Fecal inoculum
was prepared from three different human adults (male, 35y; female,
29y and male, 34y) as reported by Possemiers et al. (2004). Further,
nutritional medium, retention times, pH and temperature settings were
adopted from Possemiers et al. (2004). In order to simulate both the
luminal and mucus-associated microbial community, a mucosal com-
partment was included in the colon reactors by addition of mucin beads
as described by Van den Abbeele et al. (2012). The experimental design
of the SHIME® run included a two-week initiation period in order to
obtain a stable microbial community (Van de Wiele et al., 2015), fol-
lowed by a two-week control period for baseline measurements and a
four-week treatment period during which the synbiotic test product was
administered once daily with the nutritional medium.
2.3. Microbial metabolic activity
Samples for microbial metabolic activity were collected three times
per week during the control and treatment period from each colon
compartment. Short-chain fatty acid (SCFA) measurements, including
acetate, propionate, butyrate and branched SCFA (isobutyrate, iso-
valerate and isocaproate), were performed as reported by De Weirdt
et al. (2010). Lactate concentrations were determined using a com-
mercially available enzymatic assay kit (R-Biopharm, Darmstadt, Ger-
many) according to manufacturer’s instructions. Ammonium analysis
was performed using a KjelMaster K-375 device (Büchi, Hendrik-Ido-
Ambacht, The Netherlands). Briefly, addition of 32% NaOH liberated
ammonium from the sample in the form of volatile ammonia, which
was further distilled into a 2% boric acid solution. The ammonium in
the distillate was quantified titrimetrically with a 0.02M HCl solution.
2.4. Microbial community analysis
During the control and treatment period, samples for microbial
community analysis were collected once per week from each colon
reactor. Total DNA was isolated as described by Boon et al. (2003), with
some minor modifications. Luminal DNA originated from pelleted
bacterial cells obtained from 1mL sample, while mucosal DNA was
extracted from 0.25 g mucin agar collected from the mucus beads. A
Fastprep-24 device (MP BioMedicals, Illkirch, France) was used for
homogenization, which was conducted twice for 40 s at 4m/s with a
resting period of 5min between shakings.
Microbial community profiling of each colon compartment was es-
tablished by 16S-targeted Illumina sequencing. Aliquots of the original
genomic DNA extract were send out to LGC Genomics GmbH (Berlin,
Germany) for library preparation and sequencing on an Illumina Miseq
platform with v3 chemistry using the primers as reported by Klindworth
et al. (2013), with modification of the reverse primer (785Rmod; 5′-
GAC TAC HVG GGT ATC TAA KCC-3′) to increase coverage, which
amplified the 16S rRNA gene V3-V4 hypervariable regions.
Subsequently, quantitative polymerase chain reaction (qPCR) assays
for Lactobacillus spp., Bifidobacterium spp., Akkermansia muciniphila and
Faecalibacterium prausnitzii were completed using a QuantStudio 5 Real-
Time PCR system (Applied Biosystems, Foster City, CA USA). Each
sample was analysed in technical triplicate and outliers (more than 1 CT
difference) were removed. The qPCR assay for Lactobacillus spp. was
previously described by Furet et al. (2009), while the qPCR for Bifido-
bacterium spp. was performed as reported in Rinttilä et al. (2004). The
qPCR assays for Akkermansia muciniphila and Faecalibacterium prausnitzii
were conducted as described by Collado et al. (2007) and Sokol et al.
(2009), respectively.
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2.5. Statistics
Student’s T-tests for pairwise comparisons were performed for as-
sessment of normally distributed data of the different control and
treatment weeks for metabolic markers and microbial community
parameters. Differences were considered significant if p < 0.05.
For the 16S-targeted Illumina sequencing, read assembly and
cleanup was derived from the MiSeq procedure (Kozich et al., 2013;
Schloss and Westcott, 2011). Briefly, mothur (v. 1.39.5) was utilized to
assemble reads into contigs, perform alignment-based quality filtering
(alignment to the mothur-reconstructed SILVA SEED alignment, v.
123), remove chimeras, assign taxonomy using a naïve Bayesian clas-
sifier (Wang et al., 2007) and SILVA NR v128 and cluster contigs into
operational taxonomic units (OTUs) at 97% sequence similarity. All
sequences classified as Archaea, Chloroplasts, Eukaryota and Mi-
tochondria were omitted, as well as sequences that could not be clas-
sified, even not at (super) Kingdom level. For each OTU, representative
sequences were picked as the most abundant sequence within that OTU.
Finally, the reciprocal Simpson diversity index was calculated as re-
viewed by Bent and Forney (2008).
3. Results
3.1. Colon-region specific microbial metabolism and composition in the
SHIME®
Corresponding colon compartments of the three parallel SHIME®
setups inoculated with fecal microbiota of three different donors
showed highly comparable SCFA levels during the control period (Fig.
S1). Therefore, for optimal visualization of donor-independent colon-
region specific colonization, averages over the three units were calcu-
lated. This revealed that during the control period, the levels of mi-
crobial metabolic markers (SCFA, lactate and ammonium) were colon
region-specific, with the levels of most parameters significantly in-
creasing between subsequent colonic environments (Table 1). Lactate
concentrations were very low.
The 16S-targeted Illumina sequencing revealed that the main phyla
in the microbial community across the three different donors were
Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, Synergistetes
and Verrucomicrobia. Families that were specifically enriched in the AC
included Bifidobacteriaceae, Lactobacillaceae, Veillonellaceae and
Enterobacteriaceae (Table 2). Several families within the Firmicutes
phylum, e.g. Lachnospiraceae and Ruminococcaceae, specifically colo-
nized the distal colon areas (TC and DC), which was also observed for
the Rikenellaceae and Tannerellaceae family within the Bacteroidetes
phylum. A similar tendency was observed for the Akkermansiaceae fa-
mily, though not reaching statistical significance, mainly because donor
1 showed a much lower abundance of Akkermansiaceae (< 1%) as
compared to the other donors in the distal colon areas. Desulfovi-
brionaceae and Synergistetes specifically colonized the DC compart-
ment. Finally, a phylum-specific colonization of the lumen versus the
mucus layer was observed with higher levels of Actinobacteria in the
mucosal environment as compared to the lumen, which was especially
attributed to the significant mucosal enhancement of Bifidobacteriaceae
in all colon compartments. The luminal environment was enriched in
species from the Bacteroidetes phylum (reaching significance in the TC
and DC), while significantly higher levels of Synergistetes were ob-
served in the mucus layer.
3.2. Altered microbial metabolic activity in response to synbiotic treatment
With respect to microbial SCFA production, consistent findings were
made for the three different donors in response to the synbiotic treat-
ment (Fig. S1) so that the averages of all parameters over the three
donors were calculated per colon compartment for optimal visualiza-
tion of donor-independent treatment effects. SCFA profiles mainly
consisted of acetate, propionate and butyrate (Fig. 1) and trace amounts
of branched SCFA (Fig. 2). Treatment with the synbiotic test product
resulted in significantly higher acetate concentrations in the distal
colon areas (TC and DC) as compared to the control period, i.e. an in-
crease of 10.7 mM and 8.9mM in the TC and DC respectively. As for
propionate concentrations, the synbiotic test product resulted in sig-
nificantly decreased levels in the AC. However, during the final two
weeks of treatment, propionate levels significantly increased in the TC
and DC as compared to the control period. Butyrate levels were strongly
enhanced, reaching significantly higher levels in all colonic regions as
compared to the control period. An average increase in butyrate con-
centrations of 14.4 mM in the AC, 13.6mM in the TC and 11.1 mM in
the DC was observed upon synbiotic supplementation. Despite the low
levels of branched SCFA (Fig. 2), a significant reduction was detected in
all colon areas upon treatment with the test product. Similar effects
were observed on ammonium production (Fig. 2), with a significant
average decrease of 65.3 mg/L in the AC, 44.4 mg/L in the TC and
80.5 mg/L in the DC upon synbiotic supplementation. Finally, upon
treatment with the synbiotic test product lactate levels significantly
increased in the distal colon areas (TC & DC) (Fig. 1). Furthermore, a
trend towards increased lactate levels was observed during the final
week of treatment in the AC (p= 0.061).
3.3. Altered microbial composition in response to synbiotic treatment
Application of 16S-targeted Illumina sequencing demonstrated that
the synbiotic test product increased the diversity of the gut microbiota
across the three different donors in the distal colon areas (TC and DC),
while a decreased diversity was observed in the AC (Table 3), reaching
significance for the combined luminal and mucosal microbiota
(p= 0.015 in AC, p= 0.044 in TC and p=0.025 in DC).
With respect to alteration of community composition, it firstly fol-
lowed that the Bacillaceae family to which the probiotic strains belong
increased in all colon areas, with the strongest effect being noted in the
AC. At OTU level (Table 4), the stimulation of Bacillaceae was mainly
related to an increase in Bacillaceae OTU 59, related to Bacillus subtilis.
Further, in the AC, a significant increase in the Actinobacteria phylum
(Fig. 3) was observed, which was mainly attributed to an increase in
Bifidobacteriaceae at family level (Table 3). At OTU level (Table 4), the
stimulation of Bifidobacteriaceae was caused by the non-significant in-
crease of two Bifidobacterium OTUs, i.e. an OTU related to Bifido-
bacterium adolescentis and one related to Bifidobacterium bifidum. Ad-
ditionally, a clear trend towards increased abundance of
Lactobacillaceae was observed in the AC, which was attributed to an
increase in an OTU related to Pediococcus acidilactici (p= 0.100 in
lumen and p=0.069 in mucus).
Within the Bacteroidetes phylum, a strong increase in Prevotellaceae
Table 1
Colon-region specific colonization of metabolic activity. Average concentration
of acetate (mM), propionate (mM), butyrate (mM), lactate (mM), branched
SCFA (mM) and ammonium (mg/L) in the ascending (AC), transverse (TC) and
descending colon (DC) of the Simulator of the Human Intestinal Microbial
Ecosystem (SHIME®) during the entire control period for three different human
donors (n=6/donor). For optimal observation of consistent effects over the
different donors tested, the average of the three donors is presented (n=18).
Statistical differences between colon regions (AC vs TC vs DC) are indicated by
assigning different letters to the respective colon regions (p < 0.05).
AC TC DC
Acetate (mM) 12.2a ± 2.1 26.0b ± 2.0 30.1c ± 2.3
Propionate (mM) 2.7a ± 0.7 8.3b ± 0.7 9.4c ± 0.7
Butyrate (mM) 11.3a ± 0.9 12.7b ± 0.7 12.0c ± 0.5
Lactate (mM) 0.2a ± 0.1 0.4b ± 0.1 0.3 a,b ± 0.2
Branched SCFA (mM) 1.7a ± 0.1 2.2b ± 0.1 2.5c ± 0.1
Ammonium (mg/L) 169.5a ± 17.7 296.5b ± 27.1 354.6c ± 39.0
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Table 2
Colon-region specific colonization of microbial community. Average abundance (%) of microbial families belonging to specific phyla in the luminal (L) and mucosal
(M) environment of the ascending (AC), transverse (TC) and descending colon (DC) of the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) at the
end of the control period (n= 1/donor). For optimal observation of consistent effects over the different donors tested, the average of the three donors is presented
(n=3). Statistical differences between colon regions (AC vs TC vs DC) are indicated by assigning different letters to the respective colon regions (small letters are
used for the luminal environment, while capital letters are used for the mucosal environment). Statistical differences between the lumen and the mucus layer are
indicated by their respective p-values in each of the colon regions. P-values < 0.05 are considered as statistically significant differences.
Phylum Family Abundance (%) p-value
L M L vs M
AC TC DC AC TC DC AC TC DC
Actinobacteria Bifidobacteriaceae 7.8 a 3.0 a 3.0 a 27.6 A 16.6B 10.3B 0.006 0.006 0.024
Coriobacteriaceae 0.0 a 0.1b 0.1b 0.0 A 0.6B 1.0B 0.374 0.079 0.016
Bacteroidetes Bacteroidaceae 28.5 a 37.6 a 26.9 a 13.4 A 10.8 A 12.8 A 0.284 0.008 0.096
Prevotellaceae 9.2 a 0.7 a 0.2 a 1.5 A,B 0.1 A 0.0B 0.381 0.029 0.009
Rikenellaceae 0.0 a 0.1b 0.2b 0.0 A 0.4B 1.1C – 0.022 0.003
Tannerellaceae 0.5 a 6.2b 7.4b 0.2 A 1.4B 1.4B 0.532 0.049 0.040
Firmicutes Acidaminococcaceae 0.1 a 0.8b 1.2 a,b 0.0 A 0.5B 1.4B 0.460 0.364 0.748
Christensenellaceae 0.0 a 0.0 a 0.0 a 0.0 A 0.0 A 0.2B – 0.145 0.012
Clostridiaceae_1 0.0 a 0.0 a 0.0 a 0.0 A 0.1 A 0.6B 0.586 0.138 0.005
Erysipelotrichaceae 0.0 a 0.0 a 0.1 a 0.0 A 0.1 A,B 0.2B – 0.364 0.050
Eubacteriaceae 0.0 a 0.0 a 0.1 a 0.0 A 0.1 A,B 1.0B – 0.355 0.062
Lachnospiraceae 11.0 a 30.4b 29.6b 25.6 A 24.5 A 28.9 A 0.117 0.217 0.889
Lactobacillaceae 0.0 a 0.0 a 0.0 a 2.2 A 0.1B 0.0C 0.012 0.020 0.654
Ruminococcaceae 0.0 a 2.2 a 2.2 a 0.0 A 1.0B 4.6C 0.463 0.543 0.161
Veillonellaceae 31.9 a 11.4b 11.6b 19.0 A 5.3B 3.4B 0.069 0.094 0.019
Proteobacteria Burkholderiaceae 0.2 a,b 0.2 a 0.4b 0.2 A 0.3 A 1.0 A 0.903 0.182 0.143
Desulfovibrionaceae 0.0 a 0.8b 1.5c 0.1 A 2.9B 0.8C 0.251 0.004 0.035
Enterobacteriaceae 10.3 a 0.5b 0.3b 9.9 A 0.3B 0.1B 0.924 0.222 0.009
Pseudomonadaceae 0.7 a 0.3 a,b 0.2b 0.1 A 0.0B 0.0B 0.003 0.085 0.057
uncultured 0.0 a 0.4 a 0.5 a 0.0 A 0.4 A 0.3 A – 0.947 0.766
Synergistetes Synergistaceae 0.0 a 2.8b 12.1c 0.0 A 34.5B 29.7B 0.214 0.007 0.015
Verrucomicrobia Akkermansiaceae 0.0 a 2.5 a 2.0 a 0.0 A 0.1 A 0.7 A – 0.345 0.313
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Fig. 1. Effects on microbial metabolic activity. Average (± stdev) (A) acetate, (B) propionate, (C) butyrate and (D) lactate levels (mM) during the control (C1-C2;
n= 3/donor) and the treatment (TR1-4; n= 3/donor) weeks in the ascending (AC), transverse (TC) and descending colon (DC) of the human gastro-intestinal tract
for three human donors tested. For optimal observation of consistent effects over the different donors tested, the average of the three donors is presented per week
(n=9). Statistically significant differences relative to the first control week are indicated with *(p < 0.05).
C. Duysburgh, et al. International Journal of Pharmaceutics: X 1 (2019) 100021
4
was observed in the AC upon supplementation of the synbiotic test
product, reaching significance in the distal parts of the colon (TC and
DC). The stimulation of the Prevotellaceae family was mainly at the
expense of the Bacteroidaceae family, which significantly decreased in
abundance in the lumen of the AC and TC. As for other bacterial groups
belonging to Bacteroidetes and containing propionate-producing spe-
cies, such as Rikenellaceae and Tannerellaceae, a specific stimulation was
detected in the TC and DC. For instance, at OTU level, a significant
increase was observed in the mucosal environment of the TC and DC for
an OTU related to Parabacteroides johnsonii.
Another consistent effect upon treatment with the synbiotic test
product was a decrease in several families within the Proteobacteria
and Synergistetes phyla. Furthermore, it was found that treatment with
the synbiotic test product stimulated a wide spectrum of groups con-
taining potential butyrate-producing species, such as
Erysipelotrichaceae, Lachnospiraceae and Ruminococcaceae, with a sig-
nificant increase being observed in the abundance of an OTU related to
Faecalibacterium prausnitzii.
To confirm some of the aforementioned treatment effects of the
synbiotic formulation on specific taxonomic groups of interest
(Bifidobacterium spp., Lactobacillus spp., Faecalibacterium prausnitzii and
Akkermansia muciniphila), a quantitative approach, i.e. qPCR analysis
was performed (Fig. 4 for luminal environment and Fig. S2 for mucosal
environment). Across the three different donors, significant increases of
Bifidobacterium spp. and Lactobacillus spp. were observed in all colonic
areas in both the luminal and mucosal environment, except for
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Fig. 2. Effect on proteolytic markers. Average (± stdev) (A) branched SCFA (BCFA; mM) and (B) ammonium (mg/L) production during the control (C1-C2; n=3/
donor) and the treatment (TR1-4; n= 3/donor) weeks in the ascending (AC), transverse (TC) and descending colon (DC) of the human gastro-intestinal tract for three
human donors tested. For optimal observation of consistent effects over the different donors tested, the average of the three donors is presented per week (n=9).
Statistically significant differences relative to the first control week are indicated with *(p < 0.05).
Table 3
Treatment effect of synbiotic formulation on microbial community composition at family level. Abundance (%) of microbial families level and the Reciprocal
Simpson Diversity Index in the luminal and mucosal environment of the ascending (AC), transverse (TC) and descending colon (DC) of the human gastro-intestinal
tract at the end of the control (C) and the treatment (TR) period upon treatment with the test product (n=1/donor). For optimal observation of consistent effects
over the different donors tested, the average of the three donors (D1/2/3) is presented (n= 3). Statistically significant differences between control and treatment (C
vs TR), are indicated with *(p < 0.05).
Phylum Family Average D1/2/3
Lumen Mucus
AC TC DC AC TC DC
CTRL TR CTRL TR CTRL TR CTRL TR CTRL TR CTRL TR
Actinobacteria Bifidobacteriaceae 7.8 18.8 3.0 11.7* 3.0 13.1* 27.6 49.0* 16.6 26.6 10.3 10.6
Coriobacteriaceae 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.6 2.2 1.0 1.1
Bacteroidetes Bacteroidaceae 28.5 1.0* 37.6 16.1* 26.9 21.4 13.4 1.2 10.8 9.2 12.8 14.3
Prevotellaceae 9.2 36.7 0.7 8.3* 0.2 5.3* 1.5 14.7 0.1 0.5* 0.0 0.1*
Rikenellaceae 0.0 0.0 0.1 0.3 0.2 0.8 0.0 0.0 0.4 0.3 1.1 1.2
Tannerellaceae 0.5 0.0 6.2 6.9 7.4 10.7 0.2 0.1 1.4 2.9 1.4 3.3*
Firmicutes Acidaminococcaceae 0.1 0.1 0.8 1.6 1.2 1.2 0.0 0.1 0.5 0.9 1.4 1.3
Bacillaceae 0.0 1.0* 0.0 0.2 0.0 0.2* 0.0 0.4 0.0 0.2 0.0 0.2*
Christensenellaceae 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.4*
Clostridiaceae_1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.6 0.4
Enterococcaceae 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0
Erysipelotrichaceae 0.0 0.0 0.0 0.5* 0.1 0.5 0.0 0.0 0.1 0.6* 0.2 1.0
Eubacteriaceae 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 1.0 0.1
Lachnospiraceae 11.0 8.0 30.4 19.4 29.6 16.3 25.6 6.1 24.5 31.0 28.9 46.0*
Lactobacillaceae 0.0 8.3 0.0 1.5 0.0 1.7 2.2 11.7 0.1 0.5 0.0 0.2
Ruminococcaceae 0.0 0.0 2.2 16.1* 2.2 10.2* 0.0 0.0 1.0 8.3* 4.6 3.3
Veillonellaceae 31.9 23.5 11.4 10.7 11.6 8.2 19.0 15.4 5.3 7.8 3.4 3.6
Proteobacteria Burkholderiaceae 0.2 0.9 0.2 0.5* 0.4 0.4 0.2 0.1 0.3 0.3 1.0 0.3
Desulfovibrionaceae 0.0 0.0 0.8 0.7 1.5 0.8* 0.1 0.0 2.9 0.9* 0.8 0.6
Enterobacteriaceae 10.3 1.7* 0.5 0.1* 0.3 0.1* 9.9 0.9* 0.3 0.0 0.1 0.0*
Pseudomonadaceae 0.7 0.0* 0.3 0.2 0.2 0.1 0.1 0.0* 0.0 0.0 0.0 0.0
uncultured 0.0 0.0 0.4 0.5 0.5 0.5 0.0 0.0 0.4 0.7 0.3 0.7
Synergistetes Synergistaceae 0.0 0.0 2.8 4.1 12.1 6.3* 0.0 0.0 34.5 6.5* 29.7 10.9*
Verrucomicrobia Akkermansiaceae 0.0 0.0 2.5 0.7 2.0 1.8 0.0 0.0 0.1 0.0 0.7 0.0
Reciprocal Simpson Diversity Index 5.9 4.1 12.4 16.2 12.3 15.9 6.9 4.6 7.0 14.2 8.8 13.5
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Bifidobacterium spp. in the mucosal environment of the AC where a
trend towards increased concentrations was observed (p=0.057).
Additionally, significantly increased levels of Faecalibacterium praus-
nitzii were observed in the lumen of the TC and DC, while in the si-
mulated mucus layer increased Faecalibacterium prausnitzii concentra-
tions were detected in all colonic areas, reaching significance in the TC.
As for Akkermansia muciniphila levels, a significant reduction was de-
tected in the DC of both the luminal and mucosal environment across
the three different donors.
4. Discussion
In the present study, the effect of prolonged administration of a
synbiotic formulation, containing five spore-forming Bacillus strains
and a blend of FOS, GOS and XOS, on the human microbiome was as-
sessed for three different human individuals using the validated in vitro
M-SHIME® model (Van den Abbeele et al., 2012). A unique character-
istic of the SHIME® model is that it allows to perform mechanistic re-
search on an intestinal microbial community that, prior to treatment, is
fully stable so that treatment effects are not obscured by natural var-
iation in gut microbiome composition and functionality as is the case in
vivo (Liu et al., 2018; Possemiers et al., 2004). By applying a novel
analysis method that allowed to characterize microbiota composition at
high phylogenetic resolution, i.e. 16S-targeted sequencing of the V3-V4
Table 4
Treatment effect of synbiotic formulation on microbial community composition at OTU level. Abundance (%) at microbial OTU level in the luminal and mucosal
environment of the ascending (AC), transverse (TC) and descending colon (DC) of the human gastro-intestinal tract at the end of the control (C) and the treatment
(TR) period upon treatment with the test product (n= 1/donor). For optimal observation of consistent effects over the different donors tested, the average of the
three donors (D1/2/3) is presented (n=3). The 31 most abundant OTUs are presented together with the most abundant Bacillaceae OTU. Statistically significant
differences between control and treatment (C vs TR), are indicated with* (p < 0.05).
Phylum Family OTU Related to Average D1/2/3
Lumen Mucus
AC TC DC AC TC DC
CTRL TR CTRL TR CTRL TR CTRL TR CTRL TR CTRL TR
Actinobacteria Bifidobacteriaceae Otu0004 Bifidobacterium adolescentis 7.6 15.4 2.8 10.5* 2.7 11.9 18.2 30.0 2.7 4.0 1.0 2.0
Otu0005 Bifidobacterium bifidum 0.1 3.3 0.2 1.1 0.2 1.2* 8.8 18.4 13.3 22.0 9.0 8.2
Bacteroidetes Bacteroidaceae Otu0007 Bacteroides fragilis 8.9 0.0 10.6 0.4 7.5 0.4 4.4 0.1 2.1 1.4 3.3 1.5
Otu0008 Bacteroides dorei 6.5 0.0 4.4 2.9 5.6 3.2 7.9 0.3 3.7 1.6 2.6 1.9
Otu0009 Bacteroides uniformis 0.0 0.0 7.1 6.6 5.5 10.3 0.0 0.0 0.9 1.3 1.7 1.6
Otu0015 Bacteroides massiliensis 6.3 0.8 2.5 1.9 1.7 2.1 0.3 0.7 0.5 2.4 0.6 4.5*
Otu0017 Bacteroides intestinalis 0.0 0.0 7.4 1.6 2.9 1.7 0.0 0.0 1.6 0.2 1.0 0.5
Otu0019 Bacteroides thetaiotaomicron 0.0 0.0 1.7 0.8 1.4 1.4 0.0 0.0 0.9 1.1 2.0 2.8
Otu0022 Bacteroides ovatus 4.7 0.1* 2.0 0.6* 1.1 0.6* 0.6 0.1 0.2 0.2 0.2 0.2
Prevotellaceae Otu0006 Prevotella copri 9.1 36.6 0.7 8.3* 0.2 5.3* 1.5 14.5 0.1 0.5* 0.0 0.1*
Tannerellaceae Otu0010 Parabacteroides distasonis 0.5 0.0 5.7 4.7 6.7 7.6 0.2 0.1* 1.0 1.0 0.7 0.6
Otu0021 Parabacteroides johnsonii 0.0 0.0 0.2 1.7 0.3 2.6 0.0 0.0 0.4 1.7* 0.5 2.5*
Firmicutes Acidaminococcaceae Otu0023 Phascolarctobacterium faecium 0.0 0.0 0.8 1.6 1.2 1.2 0.0 0.0 0.5 0.9 1.4 1.3
Bacillaceae Otu0059 Bacillus subtilis 0.0 0.9* 0.0 0.2* 0.0 0.2* 0.0 0.3 0.0 0.1 0.0 0.1*
Lachnospiraceae Otu0003 Clostridium clostridioforme 10.4 1.0* 14.6 2.9* 14.3 2.4* 23.9 1.5* 11.9 5.2* 9.6 3.5*
Otu0011 Clostridium oroticum 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 6.4 19.4*
Otu0012 Blautia wexlerae 0.3 0.1 2.5 3.6 2.0 2.7 0.8 0.2 4.4 6.0 1.3 2.3*
Otu0016 Blautia faecis 0.0 0.0 2.1 5.6 2.7 5.4 0.0 0.0 0.6 3.2* 0.3 1.0*
Otu0020 Ruminococcus torques 0.0 0.0 0.4 0.6 0.8 0.7 0.0 0.0 0.4 1.3* 1.4 6.1
Otu0026 Roseburia faecis 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 2.9* 1.0 3.0
Otu0028 Lachnoclostridium sp. 0.1 2.6 0.3 1.6 0.1 0.9 0.1 4.1 0.1 0.2 0.0 0.1
Otu0029 Lachnospiraceae bacterium 0.0 0.0 2.0 0.7* 1.9 0.5* 0.0 0.0 0.7 0.4 0.3 0.1
Otu0030 Roseburia inulinivorans 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 1.0 1.5
Otu0031 Clostridium scindens 0.0 0.0 0.0 0.3 0.2 0.2 0.0 0.0 0.3 1.3 1.0 2.1
Lactobacillaceae Otu0014 Pediococcus acidilactici 0.0 8.2 0.0 1.5 0.0 1.7 2.2 11.6 0.1 0.5 0.0 0.2
Ruminococcaceae Otu0013 Subdoligranulum sp. 0.0 0.0 1.7 9.6 1.2 6.1* 0.0 0.0 0.2 5.1* 0.2 1.5*
Otu0027 Faecalibacterium prausnitzii 0.0 0.0 0.1 3.5 0.1 1.9 0.0 0.0 0.0 1.1 0.0 0.5
Otu0038 Faecalibacterium prausnitzii 0.0 0.0 0.2 2.4* 0.1 1.4* 0.0 0.0 0.0 1.0* 0.0 0.1*
Veillonellaceae Otu0001 Megasphaera sp. 28.3 21.8 10.5 10.2 11.0 7.9 10.2 13.8 3.6 6.6 1.7 2.3
Otu0025 Veillonella ratti 2.6 1.3 0.4 0.2 0.2 0.1 1.5 1.3 0.7 0.0 0.1 0.0
Enterobacteriaceae Otu0018 Enterobacter sp. 7.5 1.4 0.3 0.1 0.2 0.1 9.1 0.5* 0.2 0.0 0.0 0.0
Synergistetes Synergistaceae Otu0002 Cloacibacillus evryensis 0.0 0.0 2.7 3.8 12.0 6.0* 0.0 0.0 32.7 5.4* 29.4 10.6*
Verrucomicrobia Akkermansiaceae Otu0024 Akkermansia muciniphila 0.0 0.0 2.5 0.7 2.0 1.8 0.0 0.0 0.1 0.0 0.7 0.0
Fig. 3. Microbial community composition as assessed via 16S-targeted Illumina
sequencing. Abundance (%) at microbial phylum level in the luminal and
mucosal environment of the ascending (AC), transverse (TC) and descending
colon (DC) of the human gastro-intestinal tract at the end of the control (C;
n= 1/donor) and the treatment (TR; n= 1/donor) period upon treatment with
the test product for three human donors tested. For optimal observation of
consistent effects over the different donors tested, the average of the three
donors is presented (n= 3). Statistically significant differences relative to the
control period are indicated with *(p < 0.05).
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hypervariable regions (generating amplicons of ~425 base pairs), the
current study confirmed that the M-SHIME® model maintained a di-
verse and representative, colon region-specific luminal and mucosal
microbial community in its three consecutive colon regions. The AC was
specifically enriched with members of the Bifidobacteriaceae, Lactoba-
cillaceae, Veillonellaceae and Enterobacteriaceae, which contain several
species involved in primary substrate degradation. The establishment of
a saccharolytic microbial community in the AC confirms findings of Van
den Abbeele et al. (2010). While the AC community was physically
transferred to the distal colon (TC and DC), these regions displayed
higher abundance of microbial groups with specific metabolic functions
(Van den Abbeele et al., 2010), such as propionate-producing Tanner-
ellaceae and butyrate-producing Lachnospiraceae and Ruminococcaceae.
Furthermore, the TC and DC were characterized by a specific coloni-
zation of members of Akkermansiaceae and Synergistaceae. Recently,
Akkermansia muciniphila, the only representative of the Akkermansiaceae
family in the human gut, has been shown to degrade mucins in the
distal colon while virtually being absent in the AC (Van Herreweghen
et al., 2017). Synergistaceae on the other hand are known for their
proteolytic fermentation, which is generally favoured in distal colon
areas when sugars are depleted (Bhandari and Gupta, 2012; Liu et al.,
2018). Besides the longitudinal differences in microbial community
composition, a phylum-specific colonization of the lumen versus the
mucus layer was observed. It was previously reported that the mucosal
environment in the M-SHIME® model is specifically colonized by
members of the Firmicutes phylum, resulting in enhanced butyrate le-
vels as compared to conventional in vitro gut models (Liu et al., 2018;
Van den Abbeele et al., 2013). This was confirmed in the current study
given the mucosal enrichment of Lachnospiraceae (in the AC), Clos-
tridiaceae (in the DC) and Erysipelotrichaceae (in the DC) (Liu et al.,
2018). Further, also Actinobacteria were enriched in the mucosal en-
vironment of all colon regions, especially ascribed to increased levels of
Bifidobacteriaceae. On the other hand, the luminal environment was
characterized by higher levels of Bacteroidetes species (only significant
in TC and DC), again confirming previous findings (Liu et al., 2018; Van
den Abbeele et al., 2013), while Synergistetes specifically colonized the
mucus layer (Liu et al., 2018). The maintenance of a highly diverse and
representative colon-region specific microbiota in the SHIME® model
provided an excellent platform for doing mechanistic research to
evaluate the effect of the synbiotic treatment.
In contrast with recent observations done by our research group
upon testing the repeated daily administration of the same probiotic
strains in a similar in vitro study (Duysburgh et al., 2019), treatment
with the synbiotic test product in the current study resulted in a con-
sistent stronger increase of acetate levels in the TC and DC, propionate
levels in the DC as well as butyrate and lactate concentrations along the
entire colon (Table 5). While for the probiotic formulation a butyro-
genic effect was only shown for one of the donors tested, treatment with
the synbiotic test product in the current study resulted in a consistently
strong increase in butyrate levels for all donors tested, resulting in an
average increase that was 11.7 mM, 12.8mM and 10.8mM higher as
compared to probiotic administration in the AC, TC and DC respec-
tively. At microbial community level, this was mainly attributed to
significant increases in Faecalibacterium prausnitzii levels in the distal
colon areas, which were not observed upon probiotic supplementation
(Table 5). Furthermore, in the present study a significant increase in
Lactobacillus spp. was observed in the AC upon synbiotic administra-
tion, while this effect was absent when testing the probiotic blend alone
(Table 5). Overall, these observations stress the fact that combining
functional fibers with probiotic strains could be a useful strategy in
modulating the microbial community, as they might selectively stimu-
late different microbial groups.
With respect to the synbiotic treatment, it was observed that the
family to which the five spore-forming strains of the product belong to,
i.e. Bacillaceae, significantly increased in the AC upon supplementation,
suggesting a successful engraftment in the colonic microbiota that could
have resulted in the microbial modulation that was subsequently ob-
served. Firstly, the synbiotic treatment increased microbial diversity in
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Fig. 4. Luminal microbial community
composition as assessed via qPCR.
Average (± stdev) (A) Bifidobacterium,
(B) Lactobacillus, (C) Faecalibacterium
prausnitzii and (D) Akkermansia mucini-
phila levels (16S rRNA gene copies/mL)
over the entire control (C; n=2/
donor) and treatment (TR; n=4/
donor) period in the luminal environ-
ment of the ascending (AC), transverse
(TC) and descending colon (DC) of the
human gastro-intestinal tract for three
donors tested. For optimal observation
of consistent effects over the different
donors tested, the average of the three
donors is presented (n= 6 for C;
n=12 for TR). Statistically significant
differences between the control and
treatment period are indicated with
*(p < 0.05).
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the distal colon compartments (TC and DC), which is considered as an
important feature for the improvement of gut health, whereas de-
creased diversity was observed in the AC. Prebiotic supplementation
can indeed result in reduced bacterial diversity in the proximal colon
mainly due to stimulation of specific microbial groups at the first site of
fermentation (Zhang et al., 2015). The specific treatment effect con-
sidered a strong increase in Actinobacteria in the AC, which was mainly
attributed to a mucosal increase in Bifidobacteriaceae. Bifidobacterial
stimulation has extensively been reported upon supplementation of
prebiotic compounds like FOS (Meyer and Stasse-Wolthuis, 2009), GOS
(Depeint et al., 2008) and XOS (Makelainen et al., 2010). The strong
bifidogenic effect might have led to good cross-feeding interactions
with other resident microbiota resulting in increased levels of propio-
nate and mostly butyrate (Moens et al., 2016). While acetate is a key
metabolite of Bifidobacterium species, acetate was not increased in the
AC given its likely efficient conversion to butyrate. Butyrate is a major
energy source for the colonic epithelium and exerts several health-
promoting properties such as anti-inflammatory activity, anti-cancer
effects, promotion of satiety and reduction of oxidative stress (Hamer
et al., 2008). In the distal colon, this butyrogenic effect was mainly
associated with a significant increase in Faecalibacterium prausnitzii le-
vels. Recently it has been shown that consumption of FOS from gold
kiwifruit, as used in the present study, significantly increased Faecali-
bacterium prausnitzii levels in functionally constipated individuals
(Blatchford et al., 2017). Faecalibacterium prausnitzii exerts strong anti-
inflammatory activity in the intestinal environment which is mainly
linked with the production of butyrate stimulation of regulatory T-cells
(Furusawa et al., 2013; Sokol et al., 2008). Furthermore, increased
Faecalibacterium prausnitzii levels have been associated with reduction
of inflammatory markers (Furet et al., 2010) and reduction of en-
dotoxemia in obese subjects (Gonzalez-Sarrias et al., 2018). Interest-
ingly, McFarlin et al. reported that the same probiotic formulation as
the one that was used during the current study decreased post-prandial
metabolic endotoxemia in human subjects (McFarlin et al., 2017),
thereby suggesting a possible role of microbial intervention in tackling
obesity-related disorders.
Besides a stimulation of butyrate, also a significant increase in
acetate, lactate and propionate levels was observed in the distal colon
regions upon synbiotic supplementation over the three donors tested.
At community level, this was linked with increased abundance of an
OTU related to Prevotella copri (as part of the Prevotellaceae family)
(Hayashi et al., 2007) and one related to Parabacteroides johnsonii (as
part of the Tannerellaceae family) (Sakamoto et al., 2007), which both
produce acetate and succinate as their major metabolic end-products,
with succinate being able to be further converted to propionate by
succinate-converting, propionate producing micro-organisms such as
Bacteroides and Veillonella species (Hosseini et al., 2011). Indeed, in the
present study, increased abundance of an OTU related to Bacteroides
massiliensis was observed in the mucosal DC, which might have con-
tributed to the increased propionate levels that were observed towards
the end of the treatment period.
From this study, it can be concluded that the synbiotic formulation,
containing a mixture of five spore-forming Bacillus strains and a pre-
biotic blend of FOS, GOS and XOS, consistently affected microbial ac-
tivity and composition in the human gastrointestinal tract in vitro, with
profound effects being observed on colonic butyrate production.
Moreover, when compared with a previous study investigating the
impact of the probiotic strains on colonic functionality, the generated
data suggest a synergistic effect on the gut microbiome for the synbiotic
test product. Given the fact that the probiotic formulation has already
been shown to impact metabolic endotoxemia in human individuals, it
might be interesting to further investigate the efficacy of the synbiotic
formulation in tackling metabolic disorders.
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Table 5
Comparison of probiotic and synbiotic treatment. Average increase in acetate (mM), propionate (mM), butyrate (mM), lactate (mM), branched SCFA (mM),
Bifidobacterium (log 16S rRNA gene copies/mL), Lactobacillus (log 16S rRNA gene copies/mL), Faecalibacterium prausnitzii (log 16S rRNA gene copies/mL) and
Akkermansia muciniphila (log 16S rRNA gene copies/mL) levels in the ascending (AC), transverse (TC) and descending colon (DC) of the Simulator of the Human
Intestinal Microbial Ecosystem (SHIME®) at the end of the treatment period with the probiotic and synbiotic formulation as compared to their respective control
period for three different human donors (n= 3/donor). For optimal observation of consistent effects over the different donors tested, the average of the three donors
is presented (n= 9). Results from the probiotic formulation were retrieved from a previous study performed by our research group (Duysburgh et al., 2019).
Statistically significant differences between the probiotic and the synbiotic treatment group, are indicated with bold (p < 0.05).
AC TC DC
Synbiotic Probiotic Synbiotic Probiotic Synbiotic Probiotic
Acetate (mM) +0.02 +3.13 +10.75 +5.48 +8.94 +5.84
Propionate (mM) −0.83 +2.16 +1.75 +1.75 +2.49 +1.23
Butyrate (mM) +14.36 +2.62 +13.58 +0.80 +11.08 +0.33
Lactate (mM) +0.51 −0.04 +0.93 +0.18 +1.09 +0.11
Branched SCFA (mM) −0.23 +0.21 −0.19 +0.08 −0.22 +0.01
Bifidobacterium spp.
(log 16S copies/mL)
+0.66 +0.49 +0.48 +0.16 +0.38 −0.07
Lactobacillus spp.
(log 16S copies/mL)
+1.89 +0.23 +2.04 +0.26 +2.02 +0.14
Faecalibacterium prausnitzii
(log 16S copies/mL)
below LOD below LOD +2.96 +0.49 +2.85 +1.11
Akkermansia muciniphila
(log 16S copies/mL)
below LOD below LOD +0.76 +0.37 +0.90 −0.18
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